FLT3LG as an inflammatory hub bridging tumor immune surveillance to therapy response in breast cancer.

Clin Exp Med · 2025 · PMC12568875 · PMID 41152656

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Although FLT3LG shows highly significant correlations with these activation signatures, it lacks direct association with clinical response data from cohorts of patients treated with immune checkpoint inhibitors or CAR-T cells.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.